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Introduction
There has been increasing financial pressure with 
respect to reimbursement of targeted therapies all over 
Europe. For example, in 2014, four out of the 10 best- 
selling biopharmaceuticals (adalimumab, infliximab, 
etanercept, rituximab) were used in the field of im-
mune-mediated inflammatory diseases (IMID) including 
rheumatoid arthritis (RA), spondyloarthritides (SpA), 
psoriasis and inflammatory bowel diseases (IBD). The 
total sales of these four compounds increased from 
8.2 billion USD in 2004 to 37.7 billion in 2014 [1]. Possibil-
ities of reducing the cost would be unit price reduction, 
limitation of patient number or limitation of access to 
drugs [2]. Certainly it would be less ethical to officially 
limit access or the number of patients. Therefore, one 
needs to seek cheaper drugs.
Expiration of patient protection of several biologics 
has been occurring in recent years, between 2015 and 
2019. This enables the introduction of biosimilars that 
should be much cheaper than the bio-originators [1–3]. 
Several biosimilars of infliximab, etanercept, adalimum-
ab and rituximab have been developed. Some of them 
have already been introduced to the market and there 
are a lot more to come [1-4]. 
Yet, it seems that the only reason for using biosim-
ilars instead of bio-originators is the financial pressure 
[2–5]. There is no medical professional reason for switch-
ing a biologic to its biosimilar as biosimilars are not more 
effective or safer than their originators. In this review, we 
will briefly discuss the pros and cons of the possibility of 
switching bio-originators to biosimilars. 
The issue of biosimilarity during drug 
development
There are certain issues which may cause a prob-
lem during the development of biosimilars compared 
to the originator. Unlike small molecules, biologics are 
large proteins with a rather complex primary, second-
ary and tertiary structure. The industrial developmental 
process has several steps including DNA insertion into 
the vector, cell culture, fermentation and purification. 
Even if a very standardized manufacturing procedure is 
used, two products with the same amino acid sequence 
may still significantly differ from each other [6]. More-
over, biosimilars undergo “fast development” in order 
to save money. A full development that includes pre-
clinical, phase I, II and III studies may last for more than 
10 years. In contrast, phase II studies are omitted during 
biosimilar development that would now last for only 
7–8 years. Also biosimilars could only be studied in one 
indication and indication extrapolation can be applied to 
them [2, 6]. The issue of indication extrapolation will be 
discussed later.
On the other hand, if biosimilars and bio-originators 
are correctly compared in clinical trials, in most cases the 
high degree of similarity from pharmacological and clini-
cal points of view can indeed be confirmed. For example, 
in the EGALITY study there were overlapping pharmaco-
kinetic curves between an etanercept biosimilar and the 
originator [7]. The two molecules also showed very sim-
ilar efficacy, safety and immunogenicity in psoriasis [7].
The clinician’s dilemmas: indication 
extrapolation, interchangeability  
and substitution
As described above, biosimilar studies are usually 
conducted in one IMID and the results are extrapolat-
ed to other diseases. IMID may be similar to each other 
with respect to pathogenesis. Indeed, all IMID respond 
to TNF inhibitors. However, recent studies using biolog-
ics targeting alternative pathways have indicated that 
there may be differences even among IMID that may 
lead to unforeseen consequences regarding efficacy 
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and/or safety. For example, interleukin 6 (IL-6) inhibitors 
were effective in RA but not in SpA or psoriasis. On the 
other hand, IL-17 blockade was effective in SpA and pso-
riasis but not in RA. Moreover, anti-IL-17 treatment even 
worsened IBD. Thus, indication extrapolation even with-
in the IMID disease cluster could be a problem when de-
veloping biosimilars [2–4, 6]. 
The issue of indication extrapolation may be even 
more important if that occurs among different dis-
ease clusters. For example, the frequency of anti-ritux-
imab antibodies in RA, granulomatous polyangiitis and 
non-Hodgkin’s lymphoma is 11%, 23% and 1.1%, respec-
tively [4, 6]. Therefore, indication extrapolation among 
inflammatory and malignant diseases with highly dif-
ferent pathogenesis may lead to immunogenicity and 
maybe also efficacy and safety issues.
Interchangeability and substitution are two very 
different terms. Interchangeable biologics, including 
bio-originators and biosimilars, are expected to have 
the same clinical profile. Interchangeability is defined 
by health or regulatory authorities. On the other hand, 
substitution is when a certain prescribed medicine is 
replaced by another equivalent drug. This is usually 
a pharmacist’s decision. Automatic substitution of a bi-
ologic agent by a pharmacist, at present, is not recom-
mended and it is not allowed in the EU [4, 8]. 
The issue of (multiple) switches
Certainly the most important issue is whether one 
can switch from a bio-originator to a biosimilar just 
because of financial reasons. Again, there is no medi-
cal reason for switching an originator molecule to the 
biosimilar of the same compound [3, 4]. It has been 
suggested by meta-analyses that switching among var-
ious anti-TNF agents results in the loss of efficacy after 
the first, second, third, etc., switches. It has also been 
shown that switching from one TNF inhibitor to anoth-
er is still an option, but the third anti-TNF agent may 
have very little efficacy [4, 9]. Indeed, in our Hungarian 
cohort, switches to the second, third and fourth treat-
ment resulted in gradual loss of efficacy and decreasing 
drug survival rates [10]. As a biosimilar is “similar” to 
its bio-originator but definitely not the same, a forced 
switch from the bio-originator to the biosimilar of the 
same compound may be counted as “one more switch” 
that may, as discussed above, result in loss of efficacy.
On the other hand, in the NOR-SWITCH trial, patients 
with various IMID were treated with infliximab origina-
tor. About half of the patients were switched to the bi-
osimilar at week 52. Patients continuing the originator 
infliximab and those switched to the biosimilar did not 
show differences in safety and efficacy [11]. Also, in the 
EGALITY trial described above, some psoriasis patients 
underwent multiple switches between the etanercept 
originator and biosimilar. Psoriasis Area and Severity In-
dex (PASI) clinical responses were similar between the 
pooled continued and switched treatment arms [7]. Yet, 
these were clinical trials in a relatively small set of pa-
tients. We still lack a great amount of real-world data [5]. 
In the real world, it is still unsure whether forced switch-
es performed due to solely financial reasons would re-
sult in loss of efficacy or not. 
International recommendations
Finally, in the last published set of European League 
Against Rheumatism (EULAR) recommendations for the 
management of rheumatoid arthritis, the Task Force re-
iterated its position that “if a TNF-inhibitor fails, another 
TNF-inhibitor – but not a biosimilar of the same mole-
cule! – can be (…) effective. (…) An effective biological 
agent should not be switched to another bDMARD for 
non-medical reasons” [12]. 
Based on these recommendations, the Rheuma-
tology Section of the Hungarian Medical College also 
proposes that “when choosing a biosimilar product, the 
following professional and ethical issues need to be con-
sidered: a) an effective and safe original biologic agent 
should not be switched to a biosimilar; b) when initi-
ating biological therapy, a biosimilar alternative may be 
considered after an agreement with the patient; c) this 
is primarily an economical consideration so that more 
patients should have access to treatment” [13].
Conclusions
The introduction of a biosimilar agent is a good alter-
native during targeted therapy. It may increase patient 
access to treatment, widen the choice of health care pro-
fessionals and may be cost-effective. On the other hand, 
there are still numerous dilemmas including the possible 
effects of forced switching on efficacy and safety, issues 
of automated substitution, open questions in indication 
extrapolation and a lack of robust real-world data. Al-
though there are increasing biosimilar penetration rates 
in Northern Europe, we still need more convincing data 
and real-world experience in our region [5, 8]. 
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